The combination of Venetoclax and HMAs may synergistically exert anti-tumor effects by upregulating the expression of pro-apoptotic proteins NOXA and PUMA, while inhibiting the activity of pro-survival proteins MCL1 and BCL-XL, thereby facilitating apoptosis in AML tumors (12). This evidence concerns the gene BCL2L1 and acute myeloid leukemia.